A review of the optimal dose of either unfractionated heparin or low molecular weight heparin in the prevention of venous thromboembolism in patients with severe COVID-19: Evidence review of the clinical benefit and harm

Publication

Publication:
A review of the optimal dose of either unfractionated heparin or low molecular weight heparin in the prevention of venous thromboembolism in patients with severe COVID-19: Evidence review of the clinical benefit and harm

Blockman, M
;
Cohen, K
;
De Waal, R
;
Gray, A
;
Maartens, G
;
Nel, J
;
Parrish, A
;
Rees, H
;
Reubenson, G
;
Kredo, T

Date

2021-07-30

Publisher

South African National Department of Health

Collections

Intramural: Reports

Show all metadata

Files

Name: Blockman M_2021_A review of the.pdf

Size: 639.17 KB

Kind: Adobe PDF

Keywords

Anticoagulation,Thromboembolism,Venous,Pulmonary embolism,Clinical guidelines

URI

https://hdl.handle.net/11288/597990